These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31230007)

  • 1. Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment.
    Belcher AM; Cole TO; Greenblatt AD; Hoag SW; Epstein DH; Wagner M; Billing AS; Massey E; Hamilton KR; Kozak ZK; Welsh CJ; Weintraub E; Wickwire EM; Wish ED; Kaptchuk TJ; Colloca L
    BMJ Open; 2019 Jun; 9(6):e026604. PubMed ID: 31230007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
    Belcher AM; Cole TO; Massey E; Billing AS; Wagner M; Wooten W; Epstein DH; Hoag SW; Wickwire EM; Greenblatt AD; Colloca L; Rotrosen J; Magder L; Weintraub E; Wish ED; Kaptchuk TJ
    JAMA Netw Open; 2023 Apr; 6(4):e237099. PubMed ID: 37043203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.
    Bakouni H; McAnulty C; Tatar O; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
    Am J Addict; 2023 Sep; 32(5):469-478. PubMed ID: 37308805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial.
    Socias ME; Wood E; Dong H; Brar R; Bach P; Murphy SM; Fairbairn N
    Contemp Clin Trials; 2020 Apr; 91():105993. PubMed ID: 32194251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial.
    Ellerbroek H; van den Heuvel SAS; Dahan A; Timmerman H; Kramers C; Schellekens AFA
    Addict Sci Clin Pract; 2022 Sep; 17(1):47. PubMed ID: 36057608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive memantine for opioid use disorder treatment: A systematic review.
    Elias AM; Pepin MJ; Brown JN
    J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
    Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
    Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
    Chandler RK; Finger MS; Farabee D; Schwartz RP; Condon T; Dunlap LJ; Zarkin GA; McCollister K; McDonald RD; Laska E; Bennett D; Kelly SM; Hillhouse M; Mitchell SG; O'Grady KE; Lee JD
    Contemp Clin Trials; 2016 May; 48():166-72. PubMed ID: 27180088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of methadone treatment of arrestees: 24-month post-release outcomes.
    Schwartz RP; Kelly SM; Mitchell SG; O'Grady KE; Duren T; Sharma A; Gryczynski J; Jaffe JH
    Drug Alcohol Depend; 2021 Jan; 218():108392. PubMed ID: 33187759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. User-centred clinical decision support to implement emergency department-initiated buprenorphine for opioid use disorder: protocol for the pragmatic group randomised EMBED trial.
    Melnick ER; Jeffery MM; Dziura JD; Mao JA; Hess EP; Platts-Mills TF; Solad Y; Paek H; Martel S; Patel MD; Bankowski L; Lu C; Brandt C; D'Onofrio G
    BMJ Open; 2019 May; 9(5):e028488. PubMed ID: 31152039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation.
    Lowry N; Cowden F; Day E; Gilvarry E; Johnstone S; Murray R; Kelleher M; Mitcheson L; Marsden J
    BMJ Open; 2022 Oct; 12(10):e067194. PubMed ID: 36270754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of the Brief Pain Inventory in Patients with Opioid Addiction Receiving Methadone Maintenance Treatment.
    Dennis BB; Roshanov PS; Bawor M; Paul J; Varenbut M; Daiter J; Plater C; Pare G; Marsh DC; Worster A; Desai D; Thabane L; Samaan Z
    Pain Physician; 2016 Jan; 19(1):E181-95. PubMed ID: 26752486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Substance Use Treatment and Recovery Team (START) study: protocol for a multi-site randomized controlled trial evaluating an intervention to improve initiation of medication and linkage to post-discharge care for hospitalized patients with opioid use disorder.
    Ober AJ; Murray-Krezan C; Page K; Friedmann PD; Chan Osilla K; Ryzewicz S; Huerta S; Mazer MW; Leamon I; Messineo G; Watkins KE; Nuckols T; Danovitch I
    Addict Sci Clin Pract; 2022 Jul; 17(1):39. PubMed ID: 35902888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
    Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
    Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.